Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 112.70M P/E - EPS this Y -15.70% Ern Qtrly Grth -
Income -22.29M Forward P/E -8.75 EPS next Y 110.40% 50D Avg Chg -3.00%
Sales 25.18M PEG - EPS past 5Y - 200D Avg Chg 1.00%
Dividend N/A Price/Book 18.13 EPS next 5Y - 52W High Chg -32.00%
Recommedations 1.70 Quick Ratio 1.59 Shares Outstanding 31.50M 52W Low Chg 35.00%
Insider Own 8.34% ROA -27.66% Shares Float 26M Beta 4.04
Inst Own 21.58% ROE -129.63% Shares Shorted/Prior 3.59M/3.23M Price 4.46
Gross Margin -44.76% Profit Margin -88.52% Avg. Volume 67,761 Target Price 21.00
Oper. Margin -10.60% Earnings Date May 9 Volume 35,125 Change -2.83%
About Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.

Capricor Therapeutics, Inc. News
04/24/24 Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation
04/24/24 Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
04/10/24 Wall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should Know
03/25/24 How Much Upside is Left in Capricor (CAPR)? Wall Street Analysts Think 229.15%
03/21/24 Capricor Therapeutics to Present at Upcoming Investor Conferences
03/14/24 Earnings Beat: Capricor Therapeutics, Inc. (NASDAQ:CAPR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
03/13/24 Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year?
03/07/24 Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect?
03/06/24 Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
03/03/24 Capricor Therapeutics Full Year 2023 Earnings: Beats Expectations
03/02/24 Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2023 Earnings Call Transcript
06:06 AM Q4 2023 Capricor Therapeutics Inc Earnings Call
02/29/24 Capricor Therapeutics Inc (CAPR) Reports Encouraging Year-End Financials and Advances in DMD Therapy
02/29/24 Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
02/27/24 Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
02/22/24 Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
02/20/24 Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization
02/04/24 Market Sentiment Around Loss-Making Capricor Therapeutics, Inc. (NASDAQ:CAPR)
01/24/24 Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2
12/13/23 Capricor Therapeutics (NASDAQ:CAPR) shareholders are up 16% this past week, but still in the red over the last five years
CAPR Chatroom

User Image flash9875 Posted - 31 minutes ago

$CAPR power surge into the next galaxy. Warp speed Mr Zulu.

User Image monsong Posted - 41 minutes ago

$CAPR 5.48 is the current small wall… let’s knock it down

User Image monsong Posted - 51 minutes ago

$CAPR let’s go vertical to $9 today

User Image Keith1004 Posted - 1 hour ago

$CAPR A little bit premarket volume. More than the usual small trades.

User Image Parsnip Posted - 3 hours ago

$CAPR DJT went from 65 to 24 and then they filed a complaint with the SEC for naked short selling and the big houses threw a hissy fit. Since then DJT went from 24 to 50, just saying.

User Image Keith1004 Posted - 9 hours ago

$CAPR My prediction for the upcoming ER. It will most likely occur on May 8 or 9. The street consensus is for a loss of approximately .12 cents per share, I believe they will show positive earnings per share. Cash on hand should be $41-42 million and the outstanding share count will go up to around 31.4 million. The call should be very good but no new surprises. I believe the stock will continue to slowly rise until the next big announcement. Hopefully, the new analyst will start his coverage on CAPR with a decent 12 month share price. Q2 should be very rewarding for Capricor shareholders with the stock trading easily above its 52 week high of $8.22 per share.

User Image rogertrades Posted - 04/30/24

$CAPR https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-testing-human-allogeneic-cells-expanded-use-cell-based-medical-products FDA is literally telling Capricor what to do and then putting that in a guidance document it feels to me. The timing is eerily close

User Image flash9875 Posted - 04/30/24

$CAPR look for a tootsie roll reversal over the next few days.

User Image rogertrades Posted - 04/30/24

$CAPR cgc getting lit and shorts getting burned. Same day will come here imo. AJ needs to grow a pair and torch the fuxkers at high bridge

User Image Gatorgunk Posted - 04/30/24

$CAPR wow got a few filled at 5.17. Free money as far as I’m concerned.

User Image WBintheHouse Posted - 04/30/24

$CAPR cheap today probably not May as this looks for footing on BLA AA chatter.

User Image Trending__Now Posted - 04/30/24

$CAPR Thinking about the latest information, I'd like to give a big thanks to who's ever running the new facility. Proof of product is maintained for quality. Well done Linda and BOD for putting those people in place. With their past experience FDA approval of the manufacturing facilities shouldn't be an issue. It's a big item and it was looked after professionally. I appreciate that.

User Image rogertrades Posted - 04/30/24

$CAPR and we are out of the wedge. low vol games. someone should pound the offer and make scumbags at high bridge start sweating on their short position

User Image monsong Posted - 04/30/24

$CAPR oh hello reversal

User Image monsong Posted - 04/30/24

$CAPR 5.30 is now the largest grouping of held shares or avg cost. This price range was less than 10% of the total shares to start the month. I think we have a new base up from the 3’s where we were before.

User Image rogertrades Posted - 04/30/24

$CAPR they put us back in this wedge

User Image dnfrs Posted - 04/30/24

$CAPR It is always a good thing to get in early on a good safe investment with very high blue sky level! There are at least half a dozen very positive developments coming for CAPR in the next few weeks and months IMO. Glad to add...but basically I'm all set! Good luck to all fellow longs!

User Image Notquiteabillionaire Posted - 04/30/24

$CAPR No surprise here, but somebody sucking up shares. Sold a few hundred well above published Bid and they evaporated before my finger was done clicking the mouse button. And yet, barely 500 shares are trading every minute. I'll get them back a few pennies lower. You too can load with the MM's. And no, as stated before, I don't flip this ticker, much more active candidates out there. I was curious. Hold long and prosper.

User Image Whizz_123 Posted - 04/30/24

$CAPR If I write something I would be repeating someone or other who said everything that needs to be said. So just sitting still.

User Image flash9875 Posted - 04/30/24

$CAPR distressing to see price drop…but given the low volume it’s meaningless . Perhaps the new analyst on the call will pick up coverage. Our story data and tam sure seem to point to a much higher price.

User Image jamestrade07 Posted - 04/30/24

$CAPR This is the email address of Kristen from Cantor, [email protected] feel free to write her a polite email how you feel about her ridiculous 8$ PT

User Image Notquiteabillionaire Posted - 04/30/24

$CAPR The more things change, the more they stay the same. Walking it down on no volume. We did pick up 16 new watchers though.

User Image allscienceandmoney Posted - 04/30/24

$CAPR anybody here feel that price will remain in this area until May approval of more shares?

User Image WBintheHouse Posted - 04/30/24

$CAPR Thanks Linda and team for sharing progress of CAP-1002 as we head down the stretch. Great call. My take and maybe some. Others not so blah blah blah. When CAPR leaders communicate there is this and that, some thumbs up, some so so. When they don’t communicate, they whine and complain lol. Oh well such is life in the virtual world. End in sight, not if but when. Payday is drawing near. Good luck to all.

User Image Macme Posted - 04/29/24

$CAPR What I see is AA and nothing else. With stellar cardiac endpoints, who in their right senses will refuse AA for DMD? Do they need a new trial for other DMD types?

User Image monsong Posted - 04/29/24

$CAPR few folks here know the IP space much better than most. With a cell therapy and the challenging manufacturing process is that also released after the IP coverage lapses or what level of details are shared after IP protection lapses? The reason I bring it up is they are working on and have completed many novel ways of doing things so curious how easy even post IP protection lapsing it is to copy?

User Image Markland55 Posted - 04/29/24

$CAPR i had high hopes for the call today but it felt like an unorganized mess. Way too much information and way too many people taking turns on the microphone. I wish it was 15 minutes shorter and the Q and A session had more new analysts Linda suggested 2 year potential timeline to approval . She really needs to be replaced and even though Kristi did a good job on the 2 assays she really has no business on a phone call she sounds worse than Aj and Linda combined Hopefully this next FDA meeting provides a real outcome that we can celebrate because clearly no one cares yet about the accepted assays They need better coaching and a real CEO who spends more time discussing potential revenue streams and the path to an accelerated approval.

User Image NYTony Posted - 04/29/24

$CAPR Crazy. We get bad news, SP goes down. We get great news, the SP goes down. Markets are so rigged against retail.

User Image Cote0924 Posted - 04/29/24

$CAPR Linda…..

User Image Trending__Now Posted - 04/29/24

$CAPR From our partners website...for what it's worth. https://www.nippon-shinyaku.co.jp/file/download.php?file_id=7454

Analyst Ratings
HC Wainwright & Co. Buy Apr 25, 24
HC Wainwright & Co. Buy Mar 1, 24
Cantor Fitzgerald Overweight Jan 5, 24
HC Wainwright & Co. Buy Oct 4, 23
HC Wainwright & Co. Buy Aug 15, 23
HC Wainwright & Co. Buy Mar 16, 23
Ladenburg Thalmann Buy Oct 26, 22
HC Wainwright & Co. Buy Jan 31, 22
HC Wainwright & Co. Buy Oct 11, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Bergmann Anthony CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Oct 23 Option 1.39 2,178 3,027 2,381 10/24/23
Musket David B Director Director Oct 12 Buy 2.75 410 1,128 31,536 10/13/23
COLLIER EARL M JR Director Director Oct 10 Buy 2.83 10,000 28,300 26,856 10/12/23
Auwaerter Paul Gisbert Director Director Oct 06 Buy 2.84 5,000 14,200 5,000 10/10/23
Musket David B Director Director Oct 04 Buy 2.90 2,500 7,250 26,043 10/06/23
Litvack Frank Director Director Aug 14 Option 1.39 20,748 28,840 137,633 08/16/23
Marban Linda CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER May 12 Option 1.39 20,749 28,841 198,604 05/16/23
Avat Xavier Other Other Apr 17 Sell 64258 14,772 949,219,176 04/27/23
Avat Xavier - - Mar 28 Sell 4.06 3,000 12,180 04/07/23
Avat Xavier - - Mar 28 Option 3.46 84,791 293,377 84,791 04/07/23
Manzo Louis Director Director Feb 21 Option 1.39 1,401 1,947 62,599 02/23/23
Litvack Frank Director Director Feb 21 Option 1.39 14,027 19,498 141,800 02/23/23
DUNBAR GEORGE W JR Director Director Feb 14 Option 1.39 1,401 1,947 10,556 02/15/23
COLLIER EARL M JR Director Director Feb 14 Option 1.39 1,401 1,947 16,856 02/15/23
Krasney Karen EVP, GENERAL COUNSEL EVP, GENERAL COUNSEL Nov 03 Option 1.39 18,932 26,315 20,047 11/04/22
Avat Xavier CHIEF BUSINESS OFFIC.. CHIEF BUSINESS OFFICER Jun 29 Buy 3.72 2,500 9,300 3,000 07/07/22
Musket David B Director Director Jun 29 Option 1.39 10,796 15,006 23,543 07/01/22
Musket David B Director Director Jun 29 Sell 3.77 28,215 106,371 12,747 07/01/22
Musket David B Director Director Jun 27 Sell 4.44 17,775 78,921 40,962 06/29/22
DUNBAR GEORGE W JR Director Director Mar 29 Option 1.39 15,455 21,482 15,455 03/31/22
COLLIER EARL M JR Director Director Mar 08 Option 1.39 15,455 21,482 15,455 03/09/22